Assembly Biosciences Schedule 13G: Paradigm 5.4% Stake

Assembly Biosciences, Inc. Schedule 13G reports that Paradigm-related reporting persons and Senai Asefaw directly beneficially own specified common stock positions as of the close of business on May 4, 2026.

Rhea-AI Filing Summary

Assembly Biosciences, Inc. Schedule 13G reports that Paradigm-related reporting persons and Senai Asefaw directly beneficially own specified common stock positions as of the close of business on May 4, 2026.

The filing lists 865,251 shares (representing 5.4%) held by Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC and Senai Asefaw, M.D., and 758,963 shares (representing 4.8%) held by Paradigm BioCapital International Fund Ltd. The filing cites 15,892,608 shares outstanding as of April 10, 2026 as the denominator for the percentage calculations.

Insights

Governance Analyst

Paradigm and an associated individual report concentrated, passive holdings near 5% of outstanding shares.

The Schedule 13G shows aggregated beneficial ownership of 865,251 shares by Paradigm entities and Dr. Asefaw, recorded as 5.4% of the issuer's common stock using the issuer's April 10, 2026 outstanding share count. The filing identifies voting and dispositive power as sole for those shares.

These holdings are reported on a May 4, 2026 snapshot; subsequent disclosures would appear if ownership or intent changes.

Institutional Portfolio Specialist

Holdings indicate a meaningful passive stake from a single advisory group and affiliated fund.

The filing clarifies that the Fund and certain separately managed accounts directly own the reported shares, and that the Adviser and Adviser GP are managers; the Adviser and GP may be deemed to beneficially own the same shares through management relationships.

Percentage figures use the issuer's stated outstanding shares: 15,892,608 as of April 10, 2026; any trading or governance intentions are not stated in the excerpt.

Key Figures

Shares outstanding: 15,892,608 shares Paradigm / Asefaw holding: 865,251 shares Paradigm International Fund holding: 758,963 shares

3 metrics

Shares outstanding 15,892,608 shares as of April 10, 2026 (used to compute percentages)

Paradigm / Asefaw holding 865,251 shares reported beneficial ownership as of May 4, 2026; listed as <percent>5.4%</percent>

Paradigm International Fund holding 758,963 shares reported beneficial ownership as of May 4, 2026; listed as <percent>4.8%</percent>

Key Terms

Schedule 13G, Sole Dispositive Power, Beneficially own

3 terms

Schedule 13G regulatory

"Item 1. Name of issuer: Assembly Biosciences, Inc."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Sole Dispositive Power regulatory

"5 | Sole Dispositive Power 865,251.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Beneficially own financial

"The Fund and one or more separately managed accounts managed by the Adviser directly beneficially own the Common Stock"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Assembly Biosciences' Schedule 13G filed on 05/11/2026 disclose about ASMB ownership?

The filing discloses that Paradigm-related reporting persons and Senai Asefaw beneficially own specific positions. It lists 865,251 shares (5.4%) and 758,963 shares (4.8%), using 15,892,608 shares outstanding as of April 10, 2026 to calculate percentages.

Who are the reporting persons named in the ASMB Schedule 13G?

The reporting persons are Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., with addresses and citizenship noted in the filing.

How were the ownership percentages for ASMB calculated in the filing?

Percentages are based on the issuer's stated share count of 15,892,608 shares outstanding as of April 10, 2026, as cited in the Schedule 13G and used to compute 5.4% and 4.8% ownership figures.

Does the Schedule 13G state whether Paradigm or Dr. Asefaw control the shares of ASMB?

The filing reports that the Adviser, Adviser GP, and Senai Asefaw have sole voting and dispositive power over the listed 865,251 shares; it also explains the adviser/GP/fund relationships and includes a disclaimer limiting ownership to directly held shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 04:02 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Assembly Biosciences, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

045396207

(CUSIP Number)

05/04/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 045396207

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 865,251.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 865,251.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

865,251.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 045396207

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 865,251.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 865,251.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

865,251.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP Number(s): 045396207

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 865,251.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 865,251.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

865,251.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 045396207

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 758,963.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 758,963.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

758,963.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.8 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Assembly Biosciences, Inc.
(b)	Address of issuer's principal executive offices: Two Tower Place, 7th Floor, South San Francisco, CA 94080
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 520 Fifth Avenue, 23rd Floor, New York, NY 10036.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP Number(s): 045396207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on May 4, 2026.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 15,892,608 shares of Common Stock outstanding as of April 10, 2026, as reported by the Issuer in its Schedule 14A filed with the SEC on April 22, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	05/11/2026

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	05/11/2026

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	05/11/2026

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	05/11/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement